Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million

Home/Newsroom/

Arrowhead Pharmaceuticals Closes...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on

January 22, 2018 it closed the previously announced underwritten public

offering of 11,500,000 shares of its common stock, which included shares

issued upon the exercise in full by the underwriters of their option to

purchase 1,500,000 additional shares. The offering was priced at $5.25

per share, and the company received gross proceeds of approximately

$60.4 million, before deducting underwriting discounts, commissions and

other offering expenses payable by the company. Jefferies LLC and

Barclays Capital Inc. acted as bookrunning managers for the offering,

Cantor Fitzgerald & Co. acted as passive joint bookrunner for the

offering and Chardan and B. Riley FBR, Inc. acted as co-managers for the

offering.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. Such forward-looking statements include

statements regarding our expectations with respect to our proposed

public offering. These statements are based upon our current

expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including, without limitation, risks and uncertainties

associated with market conditions and the satisfaction of customary

closing conditions related to the proposed offering. Our Annual

Report on Form 10-K, recent and forthcoming Quarterly Reports on Form

10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss

some of the important risk factors that may affect our ability to

achieve the anticipated results, as well as our business, results of

operations and financial condition. Readers are cautioned not to place

undue reliance on these forward-looking statements. Additionally,

Arrowhead disclaims any intent to update these forward-looking

statements to reflect subsequent developments.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors

and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com

Source: Arrowhead Pharmaceuticals Inc.

News Provided by Acquire Media